Redmile Group LLC Invests $18.35 Million in BioNTech SE (NASDAQ:BNTX)

Redmile Group LLC purchased a new position in shares of BioNTech SE (NASDAQ:BNTX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 154,456 shares of the company’s stock, valued at approximately $18,345,000.

A number of other institutional investors and hedge funds have also made changes to their positions in BNTX. Candriam S.C.A. boosted its position in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after buying an additional 418,695 shares in the last quarter. Fred Alger Management LLC purchased a new stake in shares of BioNTech in the 3rd quarter worth about $59,485,000. Baillie Gifford & Co. boosted its position in shares of BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after buying an additional 31,773 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of BioNTech by 63.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock worth $2,249,000 after buying an additional 7,340 shares in the last quarter. Finally, Discovery Capital Management LLC CT purchased a new stake in shares of BioNTech in the 2nd quarter worth about $2,467,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a research report on Monday, November 18th. Bank of America boosted their price objective on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. HSBC boosted their price objective on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $93.00 to $145.00 in a report on Tuesday, September 24th. Finally, TD Cowen reduced their target price on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $138.67.

BioNTech Trading Down 0.8 %

Shares of BNTX stock opened at $114.70 on Thursday. The firm has a market cap of $27.50 billion, a P/E ratio of -54.62 and a beta of 0.22. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm’s 50-day simple moving average is $113.83 and its 200-day simple moving average is $99.12.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company’s revenue was up 38.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.73 EPS. As a group, equities analysts forecast that BioNTech SE will post -3.72 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.